실적분석 2026년 8월 10일

Hims & Hers Health ($HIMS) Q2 2026 Earnings Analysis — Revenue Beat and Full-Year Guidance Raise Can't Offset Margin Woes; Shares Slide After-Hours

Earnings Scorecard

Revenue: $753M (YoY +38%, consensus $730M) ✅ Beat

EPS: GAAP diluted net loss per share of $0.37 (consensus adjusted EPS $0.11 — different basis, not directly comparable)

Guidance: Raised — 2026 full-year revenue lifted to $3.1–$3.3 billion; adjusted EBITDA updated to $275M–$325M (Q3 revenue guided to $880M–$900M)

Stock reaction: After-hours -3.05% ($30.8) — as of 06:05 KST, August 11

The Positives

Revenue reaccelerates: Q2 revenue of $753M, up 38% YoY, beating expectations

Subscribers and ARPU: Ending subscribers of roughly 2.89 million (+19%); monthly revenue per subscriber at $92 (+21%)

International and guidance: International revenue grew more than 17x; full-year revenue outlook raised

Domestic revenue also grew 16% YoY, signaling a renewed growth momentum. The June acquisition of Eucalyptus provided a boost to international revenue, and management expects domestic growth to continue into the second half.

The Negatives

Swing to a net loss: Q2 net loss of $86.3 million (vs. net income of $42.5 million a year earlier)

Sharp gross margin decline: Gross margin of 64% (vs. 76% a year ago), a 12-percentage-point drop

Profit and cash flow: Adjusted EBITDA fell to $60.3 million; free cash flow of -$68.2 million

Revenue grew, but cost and operating expense pressure ate into profits this quarter. One-time items such as legal contingencies and acquisition-related costs also drove the GAAP loss higher, and an adjusted net loss of roughly $20.8 million remains, raising the bar on earnings quality.

What Management Said

The CEO emphasized that providing affordable healthcare access to a customer base of roughly 3 million demonstrates growth and profitability can coexist. The CFO said the reacceleration in growth and international expansion underpinned the full-year revenue raise, and expressed greater confidence in the 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

Market Reaction and What to Watch Next

Despite the revenue beat and full-year guidance raise, the combination of a gross margin decline, net loss, and lower adjusted EBITDA prompted the market to focus less on growth and more on the pace of margin recovery.

Watch whether Q3 revenue guidance ($880M–$900M) is met and whether the domestic reacceleration shows up in the numbers.

Monitor whether gross margin deteriorates further or stabilizes following the international acquisition.

The key focus will be the magnitude of margin improvement in the second half relative to the full-year adjusted EBITDA guidance of $275M–$325M.